Clinical trials: Complete Pathological Response
General Population (no Specific Condition or Disease)
Effect of Storytelling on Questionnaire Completion and Quality of Collected Data in an E-Cohort
This study is a randomized controlled trial, nested in the SKETHIS e-cohort, aiming to evaluate whether adding a modest, narrative-driven, strorytelling introduction to a Patient-Reported Outcome questionnaire increases…
- Trial name
- PEGASYS (NCT07475338)
- Testing
- Storytelling questionnaire
- Where
- France
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- SKEZI
Lupus Nephritis
Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis
Prospective, multi-center, randomized, controlled, trial to compare tacrolimus with mycophenolate mofetil (MMF) for induces complete remission in lupus nephritis patients. The study duration is one year.
- Trial name
- NCT01580865
- Testing
- Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis
- Where
- Thailand
- Volunteers
- 84 people
- Sponsor
- Ramathibodi Hospital
Triple Negative Breast Cancer (TNBC), Early Setting
LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer
LESLIE is a multicentric randomized controlled trial in patients with triple negative breast cancer receiving neoadjuvant chemo/immunotherapy (NAT).
- Trial name
- LESLIE (NCT06831955)
- Testing
- Exercise Therapy, Fasting-Mimicking Diet, SOC
- Where
- 10 sites in Belgium
- Volunteers
- 356 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
HER-2 Positive Breast Cancer
Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years
Main objective: To analyze the clinical and biological characteristics of patients with disseminated breast cancer HER2 + treated with trastuzumab that have achieved a complete remission, partial or stable disease for a period…
- Trial name
- LongHer (NCT01433926)
- Where
- 39 sites in Spain
- Volunteers
- 114 people
- Sponsor
- Asociación para el Progreso de la Oncología en Málaga
Breast Neoplasms
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer
The purpose of this study is to compare the short-term and long-term efficacies and the safeties of pirarubicin plus docetaxel(AT group) and pirarubicin plus cyclophosphamide followed by docetaxel(AC-T group) in neoadjuvant…
- Trial name
- NCT02613026
- Testing
- Pirarubicin, Docetaxel, Cyclophosphamide
- Where
- 5 sites in China
- Volunteers
- 104 people
- Sponsor
- 307 Hospital of PLA
Esophageal Squamous Cell Carcinoma
Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
To investigate the safety and activity of preoperative pembrolizumab combined with chemoradiotherapy for resectable esophageal squamous cell carcinoma (ESCC) ,20 patients enrolled in Phase Ib PALACE-1(NCT03792347).The results…
- Trial name
- PALACE-2 (NCT04435197)
- Testing
- Pembrolizumab Injection
- Where
- 2 sites in China
- Volunteers
- 143 people
- Sponsor
- Ruijin Hospital
Epithelial Ovarian Cancer, Primary Peritoneal
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
- Trial name
- ATHENA (NCT03522246)
- Testing
- Rucaparib, Nivolumab
- Where
- 238 sites in United States, Australia and 22 more
- Volunteers
- 1,097 people
- Sponsor
- pharmaand GmbH
NSCLC
Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy
This multicenter, retrospective cohort study plans to enroll patients with lung adenocarcinoma who received neoadjuvant immunotherapy prior to surgery and did not achieve pathological complete response (non-pCR) upon…
- Trial name
- NCT07179445
- Testing
- Not applicable- observational study
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
This 4 arm study will evaluate the efficacy and safety of 4 neoadjuvant treatment regimens in female patients with locally advanced, inflammatory or early stage HER2 positive breast cancer.
- Trial name
- NCT00545688
- Testing
- Herceptin, Docetaxel, Pertuzumab
- Where
- 77 sites in Australia, Austria and 16 more
- Volunteers
- 417 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
MRI-based Approaches for Multi-parametric Model to Early Predict Pathological Complete Response to Neoadjuvant Therapy in Breast Cancer
The purpose of this clinical research is to evaluate the accuracy of a multi-parametric model based on magnetic resonance imaging (MRI) in predicting pathological complete response (pCR) after the first cycle of neoadjuvant…
- Trial name
- NeoMDSS (NCT04909554)
- Where
- China
- Volunteers
- 301 people
- Sponsor
- Guangdong Provincial People's Hospital
Assess the Variation of Apparent Diffusion Coefficient
Contribution of MRI in the Evaluation of Apparent Diffusion Coefficient and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer
The main objective of the study is to assess the sensitivity and the specificity of the variation of apparent diffusion coefficient for prediction, after a course of neoadjuvant chemotherapy or after modification of the treatment…
- Trial name
- ADC (NCT01956513)
- Testing
- MRI (Magnetic resonance imaging)
- Sponsor
- Centre Jean Perrin
Breast Cancer, Neoadjuvant Chemotherapy
ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC
Breast cancer is the most common malignant tumor in women. EC-TH is one of the standard chemotherapy regimens for HER-2 positive early breast cancer(EBC). Earlier use of trastuzumab may improve DFS rate.
- Trial name
- NCT04172259
- Testing
- Doxorubicin liposome, Cyclophosphamide, Trastuzumab
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Sun Yat-sen University
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
The goal of this clinical trial is to evaluate the efficacy and safety of SHR-A1811 plus pertuzumab in combination with or without albumin-paclitaxel neoadjuvant therapy for early or locally advanced HER2-positive breast cancer.
- Trial name
- NCT06927180
- Testing
- SHR-A1811, Pertuzumab, Albumin-Paclitaxel
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Henan Cancer Hospital